Ulcerative Colitis: Five Richest Medicines and Patients
Five essential points to improve the management of patients with ulcerative colitis. Five rich explicit responses from a group of scientists, doctors and academics, with the support of patient associations, refined – for other reasons – by creating a national registry of pathology, if better suited to therapy, and by promoting an integrated relationship with I preside over the salvation of the territory. This is the content of the political orientation note “Comprehensive management of patients with UC: quality of life for the viability of the system” presented by the initiative of Senator Guido Quintino Liris and the support of the IG-IBD and friends Onlus, always committed to supporting patients with chronic inflammatory bowel disease.
Casi increasing in 2025
Ulcerative colitis is a highly disabling disease, which heavily influences work life, psychology and physics of diseases, and is also serious in the national health system more than other chronic conditions. Colpisce infatti young adult, ancora in età lavorativa, and generates a triple risk of hospitalization in response to the general population, with 250 million medical visits all year round worldwide and few than 10 million euros per patient in Europe for a medical and recovery visit. In Italy there have been approximately 160 million people (date 2019), and this has also been the cause of the general investment of the population, the projects have reached more than 330 million people in 2025.
Colitis Ulcerosa, a new oral medication to improve aderenza to therapy
Therapy, my no for tutti
For this reason, there is no resolving therapy, even if the therapeutic target (biological pharmacy, biosimilar and small molecules) carries a rapid response, even if not compared to the symptoms. And yet, a quarter of patients suffering from chronic inflammatory bowel disease (IBD cosiddette) do not receive this treatment.
The Lombardy case
In order to improve the pressure on these patients, experts indicate the possibilities of intervention strategy. First of all, it is necessary to know about them in an effective manner for patients on the national territory. There are also disparities between individuals depending on the region. “In Lombardy, for example – Flavio Caprioli, Secretary General of the IG-IBD and Doctor of Gastroenterology at the Polyclinic Hospital of Milan – we have many diverse and probably higher numbers in other regions, in view of the number of experts (36 million) who has a superior report to the national media. It is true that this can be associated with several people. One of these topics is that of the environment, there is a possible correlation between chronic inflammatory bowel disease and anxiety levels, thinking for example of all body pollution between PM 2.5 and PM 10, such as remains a problem also for other autoimmune diseases.
The second point is to protect the optimization of available risks in relation to the direct and indirect costs of malattia. The obiettivo is that of the region at the end of personalization of healing, improving therapeutic appropriateness and early identification of patients who need advanced therapy.
It is also important to achieve homogeneous breakthroughs in the territory, so that the current state of the Italian scenario is the leopard forest. “Mancano vere e proprie reti assistenziali per the MICI, and se Sicilia e Campania hanno implemented un regional PDTA” a ricordato Ambrogio Orlando, director of the Unità Operativa Semplice Dipartimentale MICI degli Ospedali Riuniti Villa Sofia – Cervello di Palermo. “The experience of Lombardy is diverse – continues Caprioli – also thanks to the IG-IBD, to the Italian group for the studio of chronic intestinal inflammatory diseases, to the scientific society that promotes clinical research and the basis of ulcerative colitis . Everyone in some places is more isolated, like Valtellina or the South-West area, where there are better rates, and also increasing the level of education and information of the doctor and the patient.”
The arrival of a new drug to treat inflammation in Crohn’s disease
Spread knowledge
This is another underlying point of the experts: to disseminate a hair culture as part of doctors’ new therapies, by promoting the management of ulcerative colitis. Obiettivo is the improvement of therapeutic appropriation and personalization of healing. “In questo modo possiamo contributorire – conclude Salvo Leonegeneral director of Amici Italia – to achieve the obligations of integration and equity in the management of chronic pathologies, in addition to what concerns cost”.
insideheadline
